Navigation Links
Shire Receives LIALDA(R) Paragraph IV Notice Letter From Zydus Pharmaceuticals
Date:5/28/2010

DUBLIN, May 28, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has received a Paragraph IV Notice Letter today from Zydus Pharmaceuticals USA, Inc. ("Zydus") advising of the filing of an Abbreviated New Drug Application ("ANDA") for a generic version of Shire's 1.2g mesalamine delayed release tablets, LIALDA(R).

LIALDA is protected by the following FDA Orange Book listed patent: U.S. Patent No. 6,773,720, Mesalazine Controlled Release Pharmaceutical Compositions (the "'720 patent"). The patent expires in 2020.

Shire is currently reviewing the details of Zydus' Paragraph IV Notice Letter. Under the Hatch-Waxman Act, Shire has 45 days from the receipt of the Notice Letter to determine if it will file a patent infringement suit. If Shire brings suit pursuant to the Hatch Waxman regulations, a stay of approval of up to 30-months will be imposed by the FDA on Zydus' ANDA.

Notes to Editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of produ
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014 Juno ... Breakthrough Therapy Designation to the company,s JCAR015 chimeric ... the treatment of relapsed or refractory B-cell acute ... partner, Memorial Sloan Kettering Cancer Center, where Phase ... "The FDA,s action is important news for ...
(Date:11/24/2014)... 24, 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... chronic pain, announced today that Sergio Traversa , ... LD MICRO "MAIN Event" Micro-Cap Growth Conference on Wednesday, ... the Luxe Sunset Bel Air Hotel, which is located ... California . The presentation is scheduled ...
(Date:11/24/2014)... -- GlySens Incorporated announced today that it has been awarded ... Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), ... The grant is intended to support human clinical evaluation ... glucose monitoring system.  Final preparations for launch of the ... before the end of 2014. "We are ...
Breaking Medicine Technology:Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3Relmada Therapeutics To Present At LD MICRO Conference 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2
... Oct. 15 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... Annual NewsMakers in the Biotech Industry Conference on Friday, ... a.m. Eastern Time.  The session may be accessed through ... Investor Relations page.  An archived version of the presentation ...
... CINCINNATI, Oct. 15  "This is a significant decision in ... advocates and the entire pharmaceutical industry," commented Benjamin H. ... an en banc hearing was not necessary and that ... plaintiff,s claim that the diet drug Redux (commonly known ...
Cached Medicine Technology:
(Date:11/26/2014)... For those with a New Year’s resolution to ... classes at the University of Colorado Anschutz Health and ... for. The 45- 60 minute classes have just started and ... fitness club memberships. , LES MILLS BODYPUMP™ exercise classes strengthen, ... aimed at fast results , By focusing on low ...
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, Jennifer E. Hill, ... from The American Association of Nurse Practitioners ... nurse practitioners. The Distinguished Preceptorship Award recognizes the ... significant contribution toward increasing the awareness and acceptance ... (AANP) is the largest full-service national professional membership ...
(Date:11/26/2014)... (HealthDay News) -- Vultures have developed highly specialized ways ... eating dead animals, researchers report. The new research ... faces and in the guts of 50 turkey vultures ... the faces of the vultures had more than 500 ... guts, the study found. The findings suggest that ...
(Date:11/26/2014)... to peanut protein in household dust may increase the ... condition eczema, a new study reveals. About 2 ... allergic to peanuts. And severe eczema in infants has ... researchers noted. The new study included 359 infants ... the amount of peanut protein the children were exposed ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Parents need to take ... concussions, an expert warns. Parents must make sure ... standard, Dr. David Dodick, chair of the American Migraine ... Clinic College of Medicine in Scottsdale, Ariz. in an ... release. Any coach involved with teens sports needs ...
Breaking Medicine News(10 mins):Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2Health News:Parents Need to Take Lead on Teen Concussion Prevention 2
... flow may be better conditioned to survive a full-blown ... University of Cincinnati (UC). , In a five-year ... when the heart experiences short periods of stress, either ... activates a protective molecular pathwayknown as JAK-STATthat protects the ...
... WuXi PharmaTech (NYSE:,WX), China,s premier provider of pharmaceutical R&D ... temporarily assume the role of,the Chairman of the Audit ... of the Audit Committee was previously held by Mr. ... his vacation., Mr. Cuong Viet Do has served ...
... drank more heavily than male peers, field study finds ... on-the-scene study of college drinking behavior shows that parties ... while themed parties encourage college women to drink more ... of college drinking have relied largely on individual behavior ...
... - President of cbm, Prof. Allen Foster,announces that cbm ... persons,with disability, not just persons with visual loss., ... Christoffel Blinden,Mission, and Christian Blind Mission, has worked to ... for persons,with visual loss., "The organization has decided ...
... 4 Health Secretary Dr.,Calvin B. Johnson today invited ... exhibit at the Farm Show for free health,screenings, fun ... Body Shop is a fun place for kids and ... running in peak condition," Dr. Johnson said.,"Everyone should stop ...
... International,Associates, Inc, administrator for the HealthShares(TM) Indexes, a ... Funds, today,announced that effective at the opening of ... ARQL ) will replace Coley Pharmaceutical, Inc.,(Nasdaq: ... Index. Coley,Pharmaceutical is being acquired by Pfizer, Inc. ...
Cached Medicine News:Health News:Mini 'stress tests' could help condition heart to survive major attack 2Health News:WuXi PharmaTech (NYSE: WX) Names Temporary Chairman of the Audit Committee 2Health News:College Drinking Games Lead to Higher Blood Alcohol Levels 2Health News:cbm Expanding its Mandate 2Health News:QED International Associates Announces Changes to the HealthShares(TM) Emerging Cancer Index 2
The new CR6-45NM non-mydriatic retinal camera is an ideal diagnostic tool for ophthalmologists, optometrists and other medical professionals, especially when it comes to detecting and monitoring diab...
An ideal choice for film photography. The new TRC-50FXC provides 35mm color and Polaroid capability....
Digital imaging for optical screening: Diabetes, glaucoma macular degeneration, and other retinal disease....
All welded construction for strength and durability. Choice of stainless steel or chrome plated models....
Medicine Products: